Business Wire

EVUSHELD (formerly AZD7442) long-acting antibody combination authorized for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody (LAAB) combination, has received emergency use authorization (EUA) in the US ...
Monthly Prescribing Reference

Evusheld Authorized for Pre-exposure Prophylaxis of COVID-19 in Certain Individuals

The EUA was supported by primary data from the phase 3 PROVENT trial. The Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Evusheld (tixagevimab co-packaged with ...
News Medical

Could neutralizing SARS-CoV-2 monoclonal antibodies pre-exposure prophylaxis be cost-effective in a population at risk for severe COVID-19?

A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
News Medical

New oral antiretroviral shows potential as long-acting HIV pre-exposure prophylaxis

A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...